ICON9: A study evaluating the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer
Who can take part
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
Women may be able to participate if they have:
- ovarian, fallopian tube or primary peritoneal cancer of high grade serous or endometrioid type.
- cancer that was sensitive to platinum-based first-line chemotherapy (carboplatin or cisplatin chemotherapy.) Platinum-sensitive means that the patient had not needed treatment within six months of having platinum-based chemotherapy and the cancer had responded to this chemotherapy.
- recently had at least four cycles of platinum-based chemotherapy for a recurrence of the cancer and the cancer is showing a response to that chemotherapy.
This is not an exhaustive list. Women interested in participating in a clinical trial should speak to their own doctor about what other criteria might apply.
About the trial
This trial looks to answer the question as to whether two different types of anti-cancer drugs, given as maintenance treatment are:
- safe
- effective
- well-tolerated
Maintenance treatment refers to drugs that are given to try to prevent or delay the cancer's return after it has responded to chemotherapy.
Drugs used in this trial:
- olaparib, a PARP inhibitor
- cediranib, a VEGF inhibitor.
Women who enter the trial will be randomised (allocated into a treatment group by a computer) into one of two treatment groups:
Group 1 – Oral olaparib 300mg twice daily and cediranib 20mg once daily.
Group 2 – Oral olaparib 300mg twice daily.
